Recurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study
Open Access
Abstract
Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.Keywords
Funding Information
- Beijing Municipal Administration of Hospitals (PX2024057)
This publication has 32 references indexed in Scilit:
- Optimizing pathological response assessment after neoadjuvant immunotherapy: linking clinical practice to drug developmentAnnals of Oncology, 2026
- Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort studyEuropean Journal of Surgical Oncology, 2024
- Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapyThe Breast, 2024
- Neoadjuvant chemoimmunotherapy shows major pathological response and low recurrence in head and neck squamous cell carcinomaClinical and Translational Oncology, 2023
- Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapyCancer Cell, 2023
- Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trialsEuropean Journal of Cancer, 2023
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)International Journal of Surgery, 2022
- Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant ChemotherapyClinical Lung Cancer, 2020
- Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2019